Bytes
Protecting airliners from missiles
Elbit Systems has conducted successful trials on its C-MUSIC anti-missile system.
The system, developed by the Israeli defense contractor, is the first of its kind in the world that offers civilian passenger airlines comprehensive protection against shoulder-launched missiles. The tests were conducted using a Boeing 707 aircraft, but sources at Elbit say the system can be employed on any airplane.MUSIC stands for Multi Spectral Infrared Countermeasure and is part of Elbit’s series of Directed IR Countermeasure products that are designed to protect aircraft from heat-seeking missiles. In addition to the C-MUSIC, which is specifically designed to protect civilian aircraft, Elbit has also developed the J-MUSIC system for protecting medium and large jet aircraft, and a MUSIC system for protecting helicopters and small to medium aircraft.According to Elbit sources, the system combines sophisticated fiber laser technology with a thermal camera and a small, highly dynamic mirror turret to provide effective, reliable and affordable protection to all types of aircraft and under all operational conditions.Development of the MUSIC system began after terrorists in 2002 fired two surface-to-air missiles at an Israeli charter plane shortly after takeoff in Mombasa, Kenya, narrowly missing the aircraft. In 2009, the Transport Ministry contracted Elbit subsidiary Electro-optics El-Op to outfit all El Al planes with the system.While the system does make the plane safer, it forces the airline to reduce the number of passengers it can carry due to weight and space requirements.Early detection and treatment of Alzheimer’sWhile neurodegenerative illnesses are not only unpreventable, incurable and largely untreatable, a new Israeli medical breakthrough may open the door to early detection and management of such illnesses, and Alzheimer’s in particular.By focusing on a number of biomarkers that indicate how healthy an organ is, NeuroQuest (www.neuro-quest.com) hopes to develop a fast and cheap way to test a patient for any signs of early stages of the illness, when the potential for delaying its progression is higher than at later stages.The science behind the patentpending technology is based on research carried out by Prof. Michal Schwartz of the Weizmann Institute of Science in Rehovot. Schwartz discovered that certain key cellular immunological components in the blood are needed for normal brain function, and that a malfunctioning of these specific cells allows illnesses to develop and progress.The discovery of these immunological components led to the establishment of the biomarkers. NeuroQuest has recently completed a human feasibility study that demonstrated diagnostic accuracy at early stages, along with the ability to monitor the progression of Alzheimer’s and ALS, also known as Lou Gehrig’s disease. The study was conducted at three hospitals in Israel and one in Houston, Texas, and NeuroQuest is now preparing for additional validation clinical studies of its diagnostic test.